Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated just now
Peer-reviewedCC BY-NC-ND 4.0In Vivo

Serum KL-6 Levels at Acute Exacerbation in Patients With Interstitial Lung Disease

  • MASAHIRO UCHIYAMA1
  • KUNIHIKO MIYAZAKI2
  • YOSUKE MAEZAWA3
  • NAOMI KAYAUCHI4
  • SHINICHIRO OKAUCHI3
  • HIROAKI SATOH3
  • RYUICHI HASEGAWA1
4 affiliations
  1. 1Department of Intensive Care Medicine, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan
  2. 2Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan
  3. 3Division of Respiratory Medicine, Mito Medical Center, Tsukuba University Hospital-Mito Kyodo General Hospital, Mito, Japan
  4. 4Faculty of Nursing, Ibaraki Christian University, Hitachi, Japan
Read full textPDFDOICite

Abstract

Background/Aim: Serum KL-6 is widely used to monitor interstitial lung disease (ILD), but its short-term behavior around acute exacerbation (AE) and its prognostic value at AE onset remain unclear. This study evaluated serial KL-6 changes before AE and their association with survival.

Patients and Methods: We retrospectively reviewed patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who underwent KL-6 measurement at two hospitals between May 2015 and June 2025. KL-6 at AE onset was compared with values one month earlier, the highest value during the preceding year, and maximum values in patients without AE. Associations with post-AE survival were assessed.

Results: Among 409 patients with ILD, KL-6 was measured at onset in 109 AE episodes among 97 patients; 142 patients without AE had at least one measurement. Median KL-6 at AE onset was higher than the median maximum value in patients without AE (1,100 vs. 690 U/ml, p=0.0001). However, paired analyses showed no significant difference between KL-6 at AE onset and the value one month earlier (n=32, p=0.092) or the highest value during the preceding year (n=58, p=0.145). KL-6 at AE onset did not differ among patients who died within 30 days, died between 30 and 90 days, or survived beyond 90 days (p=0.4307). A high KL-6 level (≥1,100 U/ml) was not associated with survival.

Conclusion: Although KL-6 levels were higher in patients with interstitial lung disease experiencing AE compared to patients without AE, they did not consistently increase immediately before AE and had limited prognostic value at AE onset.

Related

  1. Influenza-associated acute respiratory deterioration fulfilling acute exacerbation criteria in hospitalized patients with interstitial lung disease: a single-center retrospective cohort study
    Hiroshi Nakahama, Kazumasa Ogawa, Atsushi Miyamoto +5
    BMC Pulmonary MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case-control Study.
    Nahla Bashir, Olfat Fawzy, Sally Abd El-Aziz +2
    Saudi journal of medicine & medical sciencesPeer-reviewedCC BY-NC-SAFull textEpidemiology & public healthEurope PMCPMC
  3. Association of Serum Phosphate Levels with Disease Severity and Clinical Outcomes in Patients with Community Acquired Pneumonia: A Hospital-based Prospective Observational Study
    Krunal Jayeshbhai Vaghani, Sonipriya Pazhani, Viknesh Prabu Anbalagan
    Journal of Clinical and Diagnostic ResearchPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthDOAJ
  4. Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients.
    Meilin Gui, Lixia Qin, Lingling Lv +8
    Brain and behaviorPeer-reviewedCC BYFull textNeurologyEurope PMC
  5. Comparison of Serum Calcium, Phosphorus, Alkaline Phosphatase, and Intact Parathyroid Hormone Levels Between Dialysis-Dependent and Non-Dialysis-Dependent Patients With Chronic Kidney Disease: A Cross-Sectional Observational Study.
    Mustaq Ahmad, Ajesh Chandra Gupta, Yuvraj Gulati +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{uchiyama2026serum,
  title = {{Serum KL-6 Levels at Acute Exacerbation in Patients With Interstitial Lung Disease}},
  author = {MASAHIRO UCHIYAMA and KUNIHIKO MIYAZAKI and YOSUKE MAEZAWA and NAOMI KAYAUCHI and SHINICHIRO OKAUCHI and HIROAKI SATOH and RYUICHI HASEGAWA},
  journal = {In Vivo},
  year = {2026},
  month = oct,
  doi = {10.21873/invivo.14516},
  url = {https://doi.org/10.21873/invivo.14516},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Serum KL-6 Levels at Acute Exacerbation in Patients With Interstitial Lung Disease
AU  - MASAHIRO UCHIYAMA
AU  - KUNIHIKO MIYAZAKI
AU  - YOSUKE MAEZAWA
AU  - NAOMI KAYAUCHI
AU  - SHINICHIRO OKAUCHI
AU  - HIROAKI SATOH
AU  - RYUICHI HASEGAWA
PY  - 2026
DA  - 2026/10/29
JO  - In Vivo
DO  - 10.21873/invivo.14516
UR  - https://doi.org/10.21873/invivo.14516
AB  - Background/Aim: Serum KL-6 is widely used to monitor interstitial lung disease (ILD), but its short-term behavior around acute exacerbation (AE) and its prognostic value at AE onset remain unclear. This study evaluated serial KL-6 changes before AE and their association with survival.  Patients and Methods: We retrospectively reviewed patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who underwent KL-6 measurement at two hospitals between May 2015 and June 2025. KL-6 at AE onset was compared with values one month earlier, the highest value during the preceding year, and maximum values in patients without AE. Associations with post-AE survival were assessed.  Results: Among 409 patients with ILD, KL-6 was measured at onset in 109 AE episodes among 97 patients; 142 patients without AE had at least one measurement. Median KL-6 at AE onset was higher than the median maximum value in patients without AE (1,100 vs. 690 U/ml, p=0.0001). However, paired analyses showed no significant difference between KL-6 at AE onset and the value one month earlier (n=32, p=0.092) or the highest value during the preceding year (n=58, p=0.145). KL-6 at AE onset did not differ among patients who died within 30 days, died between 30 and 90 days, or survived beyond 90 days (p=0.4307). A high KL-6 level (≥1,100 U/ml) was not associated with survival.  Conclusion: Although KL-6 levels were higher in patients with interstitial lung disease experiencing AE compared to patients without AE, they did not consistently increase immediately before AE and had limited prognostic value at AE onset.
SN  - 0258-851X
SN  - 1791-7549
ER  -